Dynamic changes and overwhelmingly complex crosstalk among genomics, transcriptomics and proteomics may make the alteration in the protein level of TSTA3 more significant and useful to predict the clinical outcomes for ESCC. This evidence concerns the gene GFUS and esophageal squamous cell carcinoma.